In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species-Reference-Cited by-同舟云学术

In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species

Published:2021-02-17 Issue:3 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Papp-Wallace Krisztina M.¹²³^ORCID,Shapiro Adam B.⁴^ORCID,Becka Scott A.¹,Zeiser Elise T.¹,LiPuma John J.⁵,Lane Douglas J.⁶,Panchal Rekha G.⁶,Mueller John P.⁴,O’Donnell John P.⁴,Miller Alita A.⁴^ORCID

Affiliation:

1. Research Service, VA Northeast Healthcare System, Cleveland, Ohio, USA

2. Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA

3. Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA

4. Entasis Therapeutics, Waltham, Massachusetts, USA

5. Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA

6. Therapeutic Discovery Branch, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA

Abstract

The Gram-negative bacterial genus Burkholderia includes several hard-to-treat human pathogens: two biothreat species, Burkholderia mallei (causing glanders) and B. pseudomallei (causing melioidosis), and the B. cepacia complex (BCC) and B. gladioli , which cause chronic lung infections in persons with cystic fibrosis. All Burkholderia spp. possess an Ambler class A Pen β-lactamase, which confers resistance to β-lactams.

Funder

DOD | Defense Threat Reduction Agency

Biomedical Laboratory Research and Development, VA Office of Research and Development

Cystic Fibrosis Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01930-20

Reference45 articles.

1. Taxonomy and pathogenesis of the Burkholderia cepacia complex